CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
Status:
Recruiting
Trial end date:
2024-04-29
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects and best dose of CMP-001 and how well it
works when given together with INCAGN01949 in treating patients with stage IV pancreatic
cancer and other cancers except melanoma. CMP-001 is made up of a short piece of DNA that is
packaged in a protein, known as a virus-like particle (VLP). VLPs are detected and processed
by cells of the immune system. The DNA contained in CMP-001 activates the immune system and
recruit cells of the immune system to the tumor. INCAGN01949 is an antibody, a type of
protein, which has been shown to stimulate the immune system. Injecting CMP-001 and
INCAGN01949 directly into the tumor may work against tumor cells to slow tumor growth by
causing tumor cells to die.